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Abstract 13 
 14 
Aim 15 
This study examines estimation of seasonal influenza vaccine effectiveness (VE) for a cohort 16 
of patients attending general practice in Scotland in 2010/11.  The study focuses on the 17 
variation in estimation of VE for both virological and clinical consultation outcomes and 18 
understanding the dependency on date of analysis during the season, methodological 19 
approach and the effect of use of a propensity score model. 20 
Methods 21 
For the clinical outcomes, three methodological approaches were considered; adjusted 22 
Poisson multi-level modelling splitting consultations in vaccinated individuals into those 23 
before and after vaccination, adjusted cox proportional hazards modelling and finally the 24 
screening method.  For the virological outcome, the test-negative case-control study design 25 
was employed. 26 
Results 27 
VE was highest for the most specific outcomes of ILI (Poisson end-of-season VE=47% (95% 28 
CI: -69%, 83%); Cox VE=34% (95% CI: -64%, 73.2%); Screening VE=52.8% (95% CI: 3.8%, 29 
76.8%)) and a virological diagnosis (VE=54% (95% CI: -37%, 85%)).  Using the Cox approach, 30 
adjusted for propensity score score only gave VE=46.5% (95% CI: -30.4%, 78.0%).  31 
Conclusion 32 
Our approach illustrated the ability to achieve relatively consistent estimates of seasonal 33 
influenza VE using both specific and less specific outcomes. Construction of a propensity 34 
score and use for bias adjustment increased the estimate of ILI VE estimated from the Cox 35 
model and made estimates more similar to the Poisson approach, which models differences 36 
in consultation behaviour of vaccinated individuals more inherently in its structure.  VE 37 
estimation for the same data was found to vary by methodology which should be noted 38 
when comparing results from different studies and countries.  39 
 40 
  41 
3 
 
 
Introduction 42 
 43 
Estimates of influenza vaccine effectiveness (VE) vary by season, population examined, 44 
study methodology, outcome measured, time of estimation and statistical methodology 45 
hindering comparability between studies [1,2]. In season 2010/11 mid-season estimates of 46 
influenza VE from both laboratory confirmed cases [3-5] and consultation data [6] and end-47 
of-season estimates [7,8] have indicated seasonal influenza VE ranging from 31% to 72% 48 
with effectiveness greater in individuals who had exposure to pandemic strain-specific 49 
vaccination (PIV) in 2009/10 and trivalent seasonal influenza vaccination (TIV) in 2010/11.  50 
 51 
 52 
Laboratory-confirmed endpoints generate the highest estimates of VE with the test negative 53 
design [9] commonly used, such as in Pebody et al. [7], however using a convenience sample 54 
may lead to bias in the control group.  Cohort designs such as defined in Castilla et al. [10] 55 
allow for monitoring of clinical endpoints such as influenza-like illness (ILI) but their 56 
observational nature leads to confounding by indication - whether this be presented as the 57 
‘healthy vaccine effect’ where healthy individuals are less likely to have an outcome inflating 58 
VE (often observed with death or hospitalisation outcomes), or conversely the ‘health 59 
seeking behaviour effect’ where vaccinated individuals are more likely to consult their 60 
general practitioner decreasing VE. The monitoring of clinical endpoints which occur more 61 
commonly than ILI, such as acute respiratory illness (ARI) may lead to less reliable estimates 62 
due to reduced specificity especially if the incidence of influenza is low compared to other 63 
circulating respiratory pathogens. Consistency of the case definition used for such 64 
consultation groupings between countries is also required for comparability [2]. 65 
 66 
The statistical methodology adopted for the study depends on the data format, whether it 67 
be individual or aggregate, and the study design used.  For aggregated cohort data, the 68 
screening method [11] can be used but has limited ability to capture time dependency - an 69 
essential component for influenza vaccine effectiveness as the baseline hazard of ILI 70 
changes during the season and individuals move from an unvaccinated state to a vaccinated 71 
one at the same time as influenza is circulating. Individual-level analysis can capture this, 72 
either using a Poisson approach offsetting by person-time in the vaccinated and 73 
unvaccinated groups [12] or Cox proportional hazards [13] These differ in how changes in 74 
the levels of the hazard over time is modelled - for Poisson time is added as a covariate and 75 
the hazard assumed to be constant within each time period whereas the Cox model 76 
accounts for time implicitly and no assumption is made regarding the shape of the hazard 77 
rate over time.  Estimates from the Poisson and Cox approaches will be similar [1] if the time 78 
period is chosen appropriately and all else is equal.  The Cox approach may be inappropriate 79 
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if the proportionality assumption of the hazard between the unvaccinated and vaccinated 80 
groups over time is violated. 81 
 82 
Using a cohort of Scottish primary care patients for season 2010/11, we examine these 83 
issues using one dataset.  For all individuals in our data, we consider three consultation 84 
outcomes and laboratory confirmed infection for a nested sample of the cohort. For the 85 
consultation outcomes, VE estimated by individual-level Poisson and Cox approaches and 86 
aggregate-level screening method are compared. The use of propensity scores is explored to 87 
reduce confounding by indication in our models.  In addition, we consider weekly estimates 88 
of VE and highlight estimation issues during the season. In this way, we aim to understand 89 
the variation in influenza VE by the outcome chosen and statistical methodology used and 90 
outline the advantages and disadvantages of each. 91 
  92 
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Methods 93 
Cohort 94 
The study population is composed of individuals of the PIPeR Cohort, as described 95 
elsewhere [1]. Individual level data on influenza-related primary care consultations, 96 
vaccination records and deaths for all permanent patients from each of the 17 primary care 97 
practices is recorded. Patients who die are censored at date of death.  The cohort is 98 
assembled on 1st October 2010 and followed up until 31st March 2011.  Qualifying at risk 99 
individuals in Scotland (those aged 65 and over and individuals with chronic health 100 
condition) were offered vaccination with trivalent seasonal influenza vaccination (TIV) (see 101 
supplementary materials for details), which includes H1N1v, and had potentially received 102 
pandemic strain-specific vaccination (PIV) in season 2009/10. Vaccinations with TIV post 1st 103 
September 2010 are included. 104 
 105 
The consultation outcomes considered are: the total number of primary care influenza-like 106 
illness consultations (ILI), all acute respiratory infection consultations (which includes 107 
influenza-like illness) (ARI), and all ARI excluding those which are Asthma-related (ILIARI).  108 
Consultations occurring within 14 days of the date of TIV are not recorded as a vaccine 109 
failure. 110 
 111 
Potential confounders considered are age, gender, the presence of chronic disease 112 
(coronary heart disease, chronic liver disease, chronic respiratory disease, chronic liver 113 
disease, neurological disorders and immunosuppression), previous vaccination with 114 
seasonal or pandemic vaccination in 2009/10, the number of ILIARI consultations in the 115 
previous season (0, 1, 2+) - used as a measure of health seeking behaviour - and Carstair’s 116 
deprivation score for the area of residence [14]. For those aged under 65, chronic risk group 117 
status is assigned at the beginning of the cohort and individuals are assumed to remain in 118 
that status.  119 
Vaccine effectiveness 120 
For the consultation outcomes VE is estimated by comparing adjusted hazard rates in the 121 
vaccinated and unvaccinated using both Cox proportional hazards clustered on practice.  122 
The proportional hazards assumption is tested by visual inspection of the Schoenfeld 123 
residuals which should no trend over time if proportionality holds. This Cox estimates are 124 
compared to VE estimated from a time adjusted Poisson regression multi-level model, 125 
nested on practice.  In the Poisson model vaccination status is assigned retrospectively and 126 
further stratified – those who are not vaccinated with TIV by end of the season are classed 127 
as “never vaccinated”. Those who have a TIV by the end of the season begin in the “before 128 
vaccination” class. Their vaccination status is then a time dependent covariate which 129 
changes to “after vaccination” when the vaccine has been received.   Vaccine effect is then 130 
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calculated as a comparison of adjusted rates in the after vaccination and before vaccination 131 
group, taking into account the time, in weeks, throughout the season, and aims to make 132 
comparison between two groups which are more similar in terms of their health-care 133 
seeking behaviour (for more details see Kavanagh et al. [1])).  Both models are adjusted by 134 
all confounding factors mentioned previously. 135 
 136 
For comparison, VE estimation using the screening method [11] with aggregated GP practice 137 
level data stratified by gender, age group (0-64, 65+) and for the under 65s only risk group 138 
membership (yes/no), is illustrated for the three consultation groupings ILI, ARI and ILIARI.  139 
The screening method is run for three time periods defined by cut off periods for 140 
vaccination and consultation; vaccination by end of December/January/February and 141 
consultations in January/February/March.  For each time period, VE is estimated from the 142 
intercept term of a multi-level logistic regression model adjusted for age, sex and risk group 143 
with practice included as a random effect.  144 
 145 
Allocation bias in receiving the TIV is a problem with observational studies [15] which we 146 
attempt to eliminate using covariate adjustment. For a sensitivity analysis, we consider the 147 
use of propensity scores [16] and examine the effect this has on the end-of-season 148 
estimates using the Cox proportional hazards model.  The propensity of an individual to 149 
receive the seasonal vaccine in 2010/11 is predicted using a non-parsimonious logistic 150 
regression model based on the covariates described previously. This model is estimated on 151 
two-thirds of the data and validated on the remaining data via using the Receiver-Operating 152 
Characteristic (ROC) curve and the associated area under the curve (AUC). This score is then 153 
estimated for each individual in the cohort and used to reduce bias by two alternative 154 
methods; (i) using the deciles of the score as the only adjusting factor and (ii) one-to-one 155 
matching of vaccinated to non-vaccinated individuals based on the score (randomly within a 156 
defined caliper of 0.25 times the standard deviation of the logit of the score [17]).  157 
 158 
Virological swab tests for influenza are collected in Scotland as part of routine influenza 159 
surveillance.  These data can be linked to the PIPeR cohort, details are in [1], and a nested 160 
case control analysis is used to estimate VE using a generalised additive logistic regression 161 
model, adjusted for age, risk group status and the temporal trends in swab positivity -162 
modelled by a cubic spline based upon week of sample collection [18]. This is regarded as a 163 
gold standard as a hard laboratory endpoint is available and adjustment for confounders 164 
possible. 165 
 166 
All analysis was conducted using R version 2.14.1 [19]. 167 
  168 
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Results  169 
Demographics 170 
The 2010/11 cohort is composed of 93,380 eligible individuals, 49.8% male, mean age 40.7 171 
years, with 16.8% over 65 and 4.3% under 5 years old (Table 1) and is well matched to the 172 
population of Scotland (48.5% male, 5.6% under 5, 16.8% over 65 [20]). Of those under 65, 173 
16.3% are in at least one clinical risk group.  A total of 877 patients, 0.94% of the cohort, had 174 
at least one virology test with 642 patients tested in the period 1st October 2010 to 31st 175 
March 2011.  Whilst 50% of the cohort is female they account for 59% of those who 176 
consulted for an ILIARI and 57% of those tested. The major selection bias for virological 177 
testing is age where there is over representation, compared to consultations, among those 178 
swabbed in the 15-44 age group and under representation among children aged under 5.  179 
There is also a deprivation bias with patients in a more deprived neighbourhood more likely 180 
to be swabbed, but little bias associated with risk group membership and seasonal 181 
vaccination in the previous year.   182 
Vaccine uptake 183 
Vaccine uptake is highest in those 65 and over (66.5% for men and 65.6% for women) and 184 
for those under 65 at risk uptake is 46.8%; these figures are lower than the national figures 185 
of 75.4% in those over 65 and 56.1% in those under 65 at risk [21] possibly reflecting the 186 
more disadvantaged nature of the cohort (Table 1). Vaccination was primarily delivered in 187 
late October and November (93% of over 65s who are eventually vaccinated have been so 188 
by the end of November 2010). Overall, 19.1% of the cohort received the seasonal influenza 189 
vaccination in 2010/11.  Uptake varies between the GP practices ranging from 58.4% to 190 
77.6% for the over 65s and 35.7% to 66.6% for the under 65s at risk. 191 
Consultations 192 
Consultation rates per 1000 person days, between 1st October 2010 and 31st March 2011, 193 
split by vaccination status at the time of consultation illustrate that substantially lower ILI 194 
rate in both the unvaccinated and vaccinated compared to the less specific ILIARI and ARI 195 
consultation groupings (Table 2). Overall crude rate ratios (RR) for ILIARI and ARI show an 196 
increased risk of consultation in those vaccinated (ILIARI RR=1.2; ARI RR=1.4) but a 197 
decreased risk for ILI in the vaccinated (ILI RR=0.6).  The incidence of ILI declines linearly 198 
with age – 0.019 per 1000py in those aged 0-4 declining to 0.003 per 1000py in those aged 199 
75+.  Age modifies the reduction in risk of ILI observed with vaccination – young vaccinated 200 
individuals (aged less than 15 years) have no ILI consultations recorded indicating RR=0 but 201 
for those aged 75+ there is an increased risk of consultation with vaccination RR=1.34. There 202 
is however limited power to test this due to the small number of ILI consultations (n=18) in 203 
those vaccinated. The majority of the consultations occur in the non-vaccinated group partly 204 
reflecting that the majority of individuals in the cohort (80.9%) do not receive vaccination. 205 
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There is a steep increase in the number of consultations around the start of December with 206 
the majority of ILI consultations occurring in this month.  ILIARI consultations peaked in late 207 
December 2010 and early January 2011. 208 
Vaccine effectiveness  209 
 210 
VE estimates vary dependent on the consultation grouping, the time of measurement and 211 
the statistical method (Table 3). Generally the Poisson and screening methods generate the 212 
most similar point estimates for VE, with the Cox estimates lower. Estimates earlier in the 213 
season have wider associated confidence intervals in particular for the rarer outcome of ILI 214 
(Figure 1). End of season VE estimates are positive for all three approaches with estimates 215 
highest for ILI and lowest for ILIARI.  For ILI, both the Cox and Poisson models estimated 216 
positive protective effect however the small number of ILI events (n=190) affected the 217 
precision of the estimate and the confidence interval spanned zero (Cox ILI VE=33.7% (95% 218 
CI: -64.0, 73.2%); Poisson ILI VE=46.5% (95% CI:-69.3, 83.1)%).  For ILIARI and ARI the 219 
Poisson model gave positive significant VE and whilst point estimates from the Cox model 220 
were positive, the confidence interval spanned VE=0. For ILI, the Cox model estimated that 221 
individuals with at least 1 ILIARI consultation in the previous year were 2.3 times (95% CI: 222 
1.5, 3.5) more likely to consult with an ILI this season than those with none, and those with 223 
two or more previous consultations were 3.1 times (95% CI: 1.6, 6.2) more likely to consult 224 
with an ILI.  In the Poisson model structure the level is similar at 2.2 times (95% CI: 1.3, 3.9) 225 
and 2.7 times (95% CI 1.1, 6.8) respectively.  226 
 227 
End of season unadjusted estimates using the Cox method show negative VE for ILIARI and 228 
ARI indicating that negative confounding leading to lowered VE is present for these 229 
outcomes.  For ILI this is not the case as adjusted estimates are lower which is due to the 230 
effect modification of age. 231 
 232 
Weekly estimates illustrate that ILI VE estimation was not possible until well into the season 233 
with stable estimates obtained by mid-January (Figure 1).  For ILIARI and ARI the large 234 
numbers of events lead to more stable estimation from the beginning of November.  From 235 
November to the beginning to January the VE estimates from the Poisson model give 236 
consistently higher estimates than using Cox proportional hazards (Figure 1).  After the 237 
beginning of January, coinciding with a decrease in influenza circulating in the community 238 
[21], the estimates from these two models diverge with the estimates from the Poisson 239 
model reaching an asymptote and the Cox estimate decreasing.  Visual inspection of the 240 
schoenfeld residuals for each of ILI, ILIARI and ARI showed no trend over time and hence no 241 
violation of the proportional hazards assumption. 242 
 243 
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The propensity model had good predictive power in assigning vaccination status 244 
(AUC=0.948). Comparison of the adjustment due to the propensity score can be made by 245 
comparing to the unadjusted estimates.  The score does little to adjust for confounding in 246 
the ILI estimate where age is the main factor.  For ILIARI and ARI the score provides 247 
increases the estimates markedly and to a level greater than the individual covariate 248 
adjustment can achieve.   The matched cohort reduced the sample size substantially to 249 
13742 from a potential maximum of 32562 if each vaccinated individual could have been 250 
matched. Estimates of VE from the matched cohort were the lowest of all methods and for 251 
ILIARI showed a negative effect (Table 3).  252 
 253 
A total of 208 individuals tested positive for influenza, yielding positivity rate of 32.3%.  The 254 
majority of the swabbed patients were unvaccinated at the time of swabbing (n=561); and 255 
only 81 were swabbed post vaccination. Among those not vaccinated, swab positivity is 256 
similar among those in a risk group (34 positive, 75 negative; 31.2%) compared to those not 257 
in a risk group (160 positive, 294 negative; 35.2%).  Relatively few vaccinated patients were 258 
tested - 81 patients and only 8 were positive for H1N1v and 6 positive for Influenza B (Table 259 
4). 260 
 261 
Adjusting for the other factors in the model there was no evidence of any effect on swab 262 
positivity of age group, risk group, deprivation and gender (Table 5).  Relative to those who 263 
were unvaccinated at the time of swabbing the odds ratio of testing positive with TIV 264 
seasonal only is 0.46 (95% CI: 0.15, 1.37), corresponding to a VE of 54% (95% CI: -37, 85%).  265 
With PIV only VE=60% (95% CI: 16, 81%) and with the combination VE=72% (95% CI: 34, 266 
88%).  There is no evidence that the addition of TIV to PIV conveys additional protection 267 
(Interaction test p=0.57).  There is more imprecision when looking at H1N1v and Flu B 268 
separately and while the estimated odds ratios are less than 1 the confidence intervals are 269 
wide.  The general pattern is that the TIV has better protection against Flu B, while PIV and 270 
the combination having the better VE against H1N1v. 271 
 272 
Restricting the analysis to those targeted for vaccination reveals highest estimates for those 273 
who received both PIV and TIV; against all influenza VE=68% (95%CI: 22, 87%), against 274 
H1N1v VE=81% (95% CI 36, 94%) and against Influenza B  VE=35% (-127, 81%)  275 
276 
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Discussion 277 
 278 
Outcome 279 
For ILIARI and ARI consultations all end of season estimates of VE were statistically 280 
significant however the small number of consultations observed for ILI leads to a larger 281 
variability in the estimate and hence insignificance of the positive VE result (Cox VE=33.7% 282 
(95% CI: -64.0, 73.2%)). The point estimate is however very similar to those calculated by 283 
Castilla et al. [6] using the same method (VE=31% (95% CI 20, 40%) for medically attended 284 
ILI). The low numbers of ILI consultations observed over the season, which with the 285 
exception of the pandemic season in 2009/10 is not unusual in this cohort, do however 286 
impair the strength of the conclusions which can be reached and highlights the need to 287 
monitor various consultation groupings.  These findings of a positive VE estimate for ILIARI 288 
and ARI are of public health importance since even a low VE in these groups may have a 289 
large public health benefit.  This is because the number of people affected by these clinical 290 
conditions dwarves the size of the population recorded as having ILI and thus may have a 291 
large impact on the overall programme effectiveness of the annual seasonal influenza 292 
programme. 293 
 294 
The sample size for the virology is limited and relatively few vaccinated patients were tested 295 
with only 8 positive for H1N1v therefore VE is estimated with low precision. This clearly 296 
identifies the need for more virological testing. However in these times of financial austerity 297 
a pragmatic line has to be walked between the amount of testing that can be planned 298 
versus the public health benefit that can be derived from any expansion to the testing 299 
undertaken.   It is difficult to separately estimate the effects of TIV from the PIV and there is 300 
a suggestion that PIV has as much of a protective effect as TIV.  This is in contrast with 301 
results from the end of season 2010/11 UK case negative study [7], which has a much larger 302 
number of samples and some of the patients in this report contribute to the UK study. This 303 
study showed that PIV and TIV both had positive VE estimates in 2010/11 (PIV only: VE=28% 304 
(95% CI: -6%, 51%); TIV: VE=55% (95% CI: 31, 71%). There was a significant improvement in 305 
VE for those that had TIV compared to PIV but no significant improvement for those 306 
vaccinated with both.  This does raise an important issue for VE estimation public health – 307 
how do we account for the effect (either positive or negative) for receipt of a prior seasonal 308 
influenza vaccine and just how far back should we go in the vaccination history?  The cohort 309 
approach adopted here offers the attraction of being able to make adjustment in any 310 
estimation of VE for such concerns. 311 
 312 
Methodology 313 
There is no consensus on which cohort method should routinely be employed to provide 314 
estimated VE or which clinical endpoint should be used.  Exploratory studies such as this as 315 
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pivotal in examining the relative performance of each method when applied to one dataset. 316 
Estimates were found to vary dependent on the statistical methodology used but the 317 
conclusions reached regarding effectiveness were mainly consistent.  A summary of the 318 
advantages and disadvantages of methodologies examined is summarised in Table 6. The 319 
important public health point is that the analysis has demonstrated positive end of season 320 
point estimates of VE across all methods and consultation groupings except when using a 321 
matched propensity score analysis. The matched analysis whilst balancing the confounding 322 
variables in the unvaccinated and vaccinated groups lost a large proportion of vaccinated 323 
individuals due to an inability to find a match. This substantially reduced the number of 324 
outcomes observed with ILI numbers falling from 190 in the full cohort to 33 in the matched 325 
cohort hence affecting the estimates found. The study demonstrates some of the challenges 326 
and pit-falls to be avoided when undertaking pooling or meta-analysis of cohort estimates 327 
of vaccine effectiveness in any season. Interestingly, the adjusted screening method, which 328 
is the simplest and cheapest method for estimation of VE,  gave estimates of VE which were 329 
similar to those from the individual based method, though without the full adjustment for 330 
multiple confounding variables.  Using the Cox approach with vaccination propensity score 331 
adjustment only, was found to give higher VE than the fully adjusted Cox model. This 332 
approach may capture more of the unmeasured behaviour of individuals who do not consult 333 
or are unlikely to appear for vaccination when they should. 334 
 335 
The Poisson model with retrospective stratification of the vaccinated to permit a 336 
comparison of those vaccinated in the period before vaccination with those vaccinated in 337 
the period after vaccination allows additional adjustment for different health seeking 338 
behaviour (essentially propensity to consult) as the comparison is closer to a within person 339 
comparison. This approach gives consistently higher estimates of VE than the Cox model 340 
which is directly attributable to the stratification as this is essentially the only difference 341 
between the model. This implies that the never vaccinated individuals are less likely to 342 
consult at a magnitude greater than that captured by the propensity to consult covariate, 343 
which had a similar effect size in both models.  The differential may therefore be due to 344 
either a lack of adjustment in the Cox model for this behaviour or an over adjustment in the 345 
Poisson model. There may also be indication bias in the Poisson approach with individuals 346 
consulting and then going on to obtain the seasonal flu vaccination giving a regression to 347 
the mean problem.  The adjustment for the propensity to consult using the number of ILIARI 348 
consultations in the previous year does not capture differences in consultation likelihood 349 
given the person truly having influenza or not.  Those who have influenza may be more 350 
likely to consult than someone with another respiratory illness which may affect VE. In the 351 
before/after/never vaccination model, the variation in levels of influenza circulation 352 
throughout the season is accounted for by adjusting the model for time in weeks. We make 353 
the assumption that the temporal trend in consultations is the same in all three vaccination 354 
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groups. Given the relatively low numbers of consultations on a weekly basis, particularly for 355 
ILI, an interaction test has low power to test this assumption.  Although we find little reason 356 
to doubt the validity of this assumption it could be considered a limitation of this modelling 357 
approach. 358 
 359 
Comparison of the two methods in 2009/10 [1] gave similar VE differences for ILIARI and ARI 360 
but not for ILI where the Cox VE was higher than the Poisson approach albeit with 361 
overlapping confidence intervals. In 2009/10, ILI consultations occurred at a higher rate 362 
(0.45 per 1000 person week compared to 0.08 in 2010/11) and many of the consultations 363 
occurred in pre/during vaccination roll out, limiting comparability between the two years. 364 
Given that 2010/11 was also atypical due to the influence of both PIV and TIV, this limits the 365 
generalizability of the conclusions to other years and the analysis should be repeated in 366 
other influenza seasons. 367 
 368 
Time 369 
For the ILIARI and ARI outcomes the Cox and Poisson approaches diverge over time with the 370 
Cox VE decreasing, possibly attributable to an increased consultation rate amongst the 371 
vaccinated individuals relative to the unvaccinated or conversely a lower consultation rate 372 
in the unvaccinated individuals later in the season.  The constancy of the Poisson estimate 373 
implies that the change is not attributable to changes in the consultation rates in those 374 
vaccinated but to the consultation rates in the never vaccinated individuals.  The results 375 
appear to suggest that as the season progresses those individuals who are never vaccinated 376 
become less likely to seek an ARI or ILIARI consultation. 377 
 378 
The divergence in estimates observed for ILIARI and ARI between the methods is not 379 
observed for ILI as the majority of ILI consultations occur by the end of January [21] whereas 380 
the consultations for ILIARI and ARI continue to occur.    381 
 382 
An alternative explanation for the Cox VE decreasing over time could be that either the 383 
immunity derived from vaccination waned over time or that antigenic drift resulted in the 384 
vaccine being less well matched to the circulating virus over time.  Evidence of reducing VE 385 
for ILI over the season exists for the 2011/12 [22] and 2012/13 season (in preparation). 386 
 387 
Conclusion  388 
In conclusion, the results show that both individual based methodologies whilst not 389 
producing identical results produced broadly consistent conclusions regarding VE – namely 390 
that the seasonal influenza vaccine provided protection against influenza and its 391 
complications in the 2010/11 season.  The Poisson model structure with further 392 
stratification of the unvaccinated group is more sensitive in accounting for healthcare 393 
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seeking behaviour over and above covariate adjustment however other methods trend in 394 
the same direction giving consistent results i.e. whichever method is used the estimated VE 395 
shows similar changes over time.     Whilst virological data is known to produce gold 396 
standard results, it is expensive.  The small number of tests conducted in vaccinated 397 
individuals consequentially limits interpretation.  In Scotland this issue has been 398 
acknowledged with current steps being taken to increase both the size of the cohort under 399 
observation and allocation of increased resource to enable increased numbers of swabs to 400 
be processed from patients with ILI and other ARI across all ages.  In the absence of 401 
increased testing clinical outcomes can be used as a surrogate.  Ideally the most specific 402 
clinical outcome would be used but ILI numbers may limit this, particularly for early season 403 
estimation.  In such cases ARI can be used whilst bearing in mind the reduced specificity and 404 
likely lower estimates that will be produced. Given the variability of virus characteristics and 405 
vaccine effectiveness it would be advisable that the application of these different methods 406 
is validated in repeated seasons. 407 
 408 
The differentials in VE due to outcome, time of analysis and method must be recognised 409 
when comparing or pooling results across different studies/countries.  Networks such as I-410 
MOVE (Influenza MOnitoring Vaccine Effectiveness) [23] facilitate discussion and planning 411 
for how this might take place in the future.  412 
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(NHS Dumfries & Galloway), Hospital Hill Surgery (NHS Fife), Denny Cross Medical Centre 424 
(NHS Forth Valley), Yell Health Centre (NHS Shetland),Newton Port Surgery, Craigshill Health 425 
Centre (both NHS Lothian). Scottish Government – Gareth Brown, Rona Watters. 426 
 427 
  428 
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 525 
TABLES 526 
Table 1:  Comparison of the distributions of explanatory variables in the whole 527 
cohort, among those in the cohort who consulted and among those in the cohort who 528 
had a virological swab for symptoms commensurate with influenza.  529 
Variable Cohort 
Total=93380 
Number (%) 
At least 1 ILIARI 
consultation 
Total=3764 
Number (%) 
Influenza 
virology test 
Total=877 
Number (%) 
Gender 
Male 
Female 
 
46,489 (49.8%) 
46,891 (50.2%) 
 
1561 (41.5%) 
2203 (58.5%) 
 
378 (43.1%) 
499 (56.9%) 
Age group 
0-4 
5-14 
15-44 
45-64 
65+ 
 
4052   (4.3%)         
9581 (10.3%)  
39290 (42.1%)         
24777 (26.5%)  
15,680 (16.8%) 
 
850 (22.5%) 
529 (14.1%) 
1079 (28.7%) 
772 (20.5%) 
534 (14.2%) 
 
122 (13.9%) 
101 (11.5%) 
363 (41.4%) 
214 (24.4%) 
77   (8.8%) 
Pandemic vaccination in 
2009/10 
Yes 
No 
 
 
13,772 (14.7%) 
 79,608 (85.3%) 
 
 
872 (23.2%) 
2892 (76.8%) 
 
 
164 (18.7%) 
713 (81.3%) 
Seasonal vaccination in 
2009/10 
Yes 
No 
 
 
16,949 (18.2%) 
  76,431  (81.8%) 
 
 
841 (22.3%) 
2923 (77.7%) 
 
 
175 (20.0%) 
702 (80.0%) 
In a chronic disease risk group 
 
Yes 
No 
 
 
14,146 (15.1%) 
79,234 (84.9%) 
 
 
782(20.8%) 
2982 (79.2%) 
 
 
200 (22.8%) 
677 (77.2%) 
Carstairs Quintile deprivation 
1 (Low) 
2 
3 
4 
5 (High) 
Unknown 
 
8221 (8.8%) 
15035 (16.1%) 
19886 (21.3%) 
20910 (22.4%) 
28907 (31.0%) 
421 (0.5%) 
 
281 (7.5%) 
656 (17.4%) 
693 (18.4%) 
868 (23.1%) 
1246 (33.1%) 
20 (0.5%) 
 
48 (5.5%) 
103 (11.7%) 
145 (16.5%) 
181 (20.6%) 
400 (45.6%) 
0 (0.0%) 
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Table 2: Consultations (Number events/person days at risk and Rate per 1000 person days) between 1st October 2010 and 31st March 2011 
stratified by vaccine status, gender, age and risk group (all individuals aged 65 or over are considered at risk).   
 
Age 
In at least 
1 chronic 
risk group Gender 
ILI in the 
unvaccinated 
ILI in the 
vaccinated 
ILIARI in the 
unvaccinated 
ILIARI in the 
vaccinated 
ARI in the 
unvaccinated 
ARI in the 
vaccinated 
Under65 No Female 
82/5584219 
0.0147 
0/106631 
0.0000 
2173/5584219 
0.3891 
40/106631 
0.3751 
2196/5584219 
0.3933 
53/106631 
0.4970 
Under65 Yes Female 
15/786411 
0.0191 
6/402708 
0.0149 
416/786411 
0.5290 
225/402708 
0.5587 
831/786411 
1.0567 
407/402708 
1.0107 
Under65 No Male 
58/6021612 
0.0096 
3/55025 
0.0545 
1659/6021612 
0.2755 
19/55025 
0.3453 
1701/6021612 
0.2825 
22/55025 
0.3998 
Under65 Yes Male 
11/741990 
0.0148 
2/356127 
0.0056 
263/741990 
0.3545 
163/356127 
0.4577 
566/741990 
0.7628 
257/356127 
0.7217 
65+ 
 
Female 
5/767860 
0.0065 
3/818944 
0.0037 
231/767860 
0.3008 
310/818944 
0.3785 
267/767860 
0.3477 
371/818944 
0.4530 
65+ 
 
Male 
1/579815 
0.0017 
4/639959 
0.0063 
155/579815 
0.2673 
215/639959 
0.3360 
179/579815 
0.3087 
248/639959 
0.3875 
Overall   
172/14481907 
0.0119 
18/2379394 
0.0075 
4897/14481907 
0.3381 
972/2379394 
0.4085 
5740/14481907 
0.3963 
1358/2379394 
0.5707 
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  Consultation group 
Date Method ILI ILIARI ARI 
31/01/2011 Cox 37.9 (-33.0, 71.0) 20.8 (-0.8, 37.7) 30.3 (7.4, 47.5) 
Poisson 
Before/After 
52.9 (-65.0, 86.5) 47.6 (39.8, 54.4) 61.0 (56.3, 65.1) 
Screening 
Adjusted 
50.3 (-12.7, 78.1) 47.0 (31.4, 59.0) 52.9 (37.3, 64.6) 
28/02/2011 Cox 30.3 (-83.8, 70.0) 18.8 (-0.9, 34.8) 27.1 (3.7, 44.9) 
Poisson 
Before/After 
49.3 (-21.1, 78.7) 45.7 (38.2, 52.4) 59.9 (55.5, 63.9) 
Screening 
Adjusted 
53.7 (0.2, 78.5) 46.7 (33.8, 57.1) 51.9 (37.2, 63.1) 
End of 
season 
31/03/2011 
Cox 33.7 (-64.0, 73.2) 10.8 (-8.4, 26.6) 18.5 (-5.3, 36.9) 
Poisson 
Before/After 
46.5 (-69.3, 83.1) 42.2 (34.5, 48.9) 57.5 (53.1, 61.5) 
Screening 
Adjusted 
52.8 (3.8, 76.8) 37.9 (24.3, 49.0) 43.0 (27.2, 55.4) 
Cox 
unadjusted 
46.9 (-10.0, 74.4) -17.9 (-49.6, 7.1) -45.4 (-15.4, -83.2) 
Cox Adjusted 
by 
propensity 
score deciles 
only 
46.5 (-30.4, 78.0) 20.1 (3.0, 34.1) 30.2 (9.6, 46.2) 
Cox Matched 
cohort – no 
adjustment 
24.1 (-77.4, 67.5) -5.9 (-25.6, 
10.7) 
12.7 (-5.8, 27.9) 
Table 3: Vaccine effectiveness estimates, split by consultation grouping examined, statistical 
method used and analysis date. 
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Table 4:  Numbers and crude Odds Ratios, 95% Confidence Intervals, and p value for testing 
an association between flu status and vaccine status at the time the swab was collected.  
Results are presented for Any Influenza Positivity, H1N1v positivity only and Influenza B 
positivity only.  Vaccine status is presented in two ways.  Vaccinated at swab refers only to 
the TIV seasonal vaccine in 2010-11 while Vaccine Status at swab refers to the combination 
of TIV seasonal vaccine in 2010-11 and monovalent pandemic vaccination in 2009-10. 
  
Any Positivity H1N1 Positive Only Flu B Positive Only
No Yes OR LCL UCL P Yes OR LCL UCL P Yes OR LCL UCL P
All Patients
Vaccinated No 369 194 1.00 119 1.00 73 1.00
at Swab Yes 67 14 0.40 0.21 0.71 0.001 8 0.38 0.16 0.77 0.006 6 0.46 0.17 1.03 0.061
Under 65 and In a risk group for vaccination or 65+
Vaccinated No 75 34 1.00 24 1.00 10 1.00
at Swab Yes 64 14 0.49 0.23 0.97 0.042 8 0.40 0.16 0.92 0.030 6 0.71 0.23 2.05 0.533
Under 65 and not in a risk group for vaccination
Vaccinated No 294 160 1.00 95 1.00 63 1.00
at Swab Yes 3 0 0.00 0.00 4.49 0.274 0 0.00 0.00 7.59 0.434 0 0.00 0.00 11.49 0.561
All Patients
Vaccine Status Unvaccinated 321 183 1.00 112 1.00 69 1.00
at Swab Pandemic Only 48 11 0.41 0.20 0.78 0.005 7 0.43 0.17 0.91 0.027 4 0.40 0.12 1.03 0.059
Seasonal Only 18 5 0.50 0.16 1.28 0.157 4 0.66 0.18 1.82 0.443 1 0.29 0.01 1.46 0.159
Both 49 9 0.33 0.15 0.65 0.001 4 0.24 0.07 0.61 0.001 5 0.49 0.16 1.17 0.113
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Table 5:  Parameter estimates (odds ratios and 95% confidence intervals) from the 
generalised additive model for swab positivity from models including the combination of TIV 
seasonal vaccine 2010-11 as well as last season’s monovalent pandemic vaccine.  
Adjustment was made for Age group and risk group membership.  Separate analyses were 
carried out for all patients and those targeted for vaccination (those over 65 or under 65 
and in a risk group) and for overall flu positivity, H1N1v positivity only of Flu B positivity 
only. 
  
Overall Flu Positivity H1N1 Positivity Flu B Positivity
All Patients OR LCL UCL P OR LCL UCL P OR LCL UCL P
Intercept 0.41 0.23 0.72 0.002 0.23 0.11 0.46 0.000 0.12 0.05 0.29 0.000
Vaccine Unvaccinated 1.00 1.00 1.00
Pandemic Only 0.40 0.19 0.84 0.016 0.46 0.19 1.15 0.096 0.36 0.12 1.12 0.077
Seasonal Only 0.46 0.15 1.37 0.165 0.65 0.19 2.23 0.497 0.20 0.02 1.68 0.138
Both 0.28 0.12 0.66 0.004 0.19 0.06 0.62 0.006 0.43 0.14 1.37 0.153
Age Group 0-4 1.00 1.00 1.00
5-14 1.60 0.76 3.35 0.217 0.58 0.20 1.69 0.321 3.48 1.30 9.31 0.013
15-64 1.06 0.59 1.92 0.835 1.12 0.55 2.26 0.760 1.06 0.44 2.58 0.895
65+ 0.76 0.28 2.07 0.588 0.96 0.28 3.25 0.950 0.66 0.14 2.99 0.585
Risk Group No 1.00 1.00 1.00
Yes 1.13 0.68 1.90 0.635 1.09 0.60 1.99 0.777 1.13 0.53 2.43 0.748
Under 65 and in risk group or Age 65+ OR LCL UCL P OR LCL UCL P OR LCL UCL P
Intercept 1.11 0.08 14.56 0.939 0.27 0.13 0.59 0.001 0.48 0.02 10.00 0.634
Vaccine Unvaccinated 1.00 1.00 1.00
Pandemic Only 0.43 0.13 1.39 0.157 0.37 0.09 1.50 0.163 0.81 0.14 4.88 0.822
Seasonal Only 0.60 0.19 1.94 0.396 0.77 0.21 2.84 0.690 0.40 0.04 3.80 0.426
Both 0.32 0.13 0.78 0.012 0.19 0.06 0.64 0.007 0.65 0.19 2.27 0.499
Age Group 0-4 1.00 1.00 1.00
5-14 0.32 0.01 7.90 0.489 1.00 0.45 0.01 13.49 0.643
15-64 0.41 0.03 6.03 0.512 1.00 0.15 0.01 3.00 0.214
65+ 0.26 0.02 4.30 0.349 0.81 0.27 2.42 0.703 0.09 0.00 2.27 0.146
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Method Advantages Limitations Possible indications/ 
recommendations 
Cox cohort  Prospective framework 
in assigning vaccination 
status 
 Individuals can have 
multiple consultation 
outcomes 
 Confounder adjustment  
 Proportionality of the influenza 
rates between unvaccinated and 
vaccinated individuals over time 
assumed 
 VE may be underestimated if 
covariate adjustment for 
healthcare seeking behaviour is 
not sufficient  
 Flexible method for 
analysis throughout 
the season  
Poisson 
before/after/never 
cohort 
 VE calculated by 
comparing consultation 
rates before and after 
vaccination reducing 
health seeking behaviour 
bias 
 Individuals can have 
multiple consultation 
outcomes 
 Confounder adjustment 
 Assumes health care seeking 
behaviour is the same before and 
after vaccination 
 Retrospective framework in 
assigning vaccination status 
 Assumes the pattern of the trends 
over time to be similar in the 
three groups though the levels 
can be different 
 Useful for end of 
season analysis if it 
is felt that 
unmeasured 
confounding due to 
differences in 
health seeking 
behaviour is 
present 
Screening   Can estimate VE when 
only aggregate level 
information is known 
 
 Limited ability to adjust for 
temporal trends in influenza  
 Only records dichotomous 
consultation outcome (at least 
one yes/no) per individual 
 Vaccination status is static 
 Lack of adjustment for healthy 
vaccine effect 
 Limited confounder adjustment 
 Useful when 
individual level 
data is not 
available  
Test negative  Highly specific outcome 
as uses virologically 
confirmed results 
 Excludes individuals with 
influenza who do not 
seek care, avoiding bias 
due to misclassifying 
non-consulting infected 
individuals as not 
infected 
 Avoids confounding by 
health care seeking 
behaviour by restricting 
population to those who 
seek care 
 May be limited by small sample 
size especially in the vaccinated 
individuals resulting in wide 
confidence intervals.   
 Assumes incidence of non-
influenza respiratory infections is 
similar between the vaccinated an 
unvaccinated 
 Assumes influenza VE does not 
vary across health-seeking strata 
 Method of choice 
for “gold-standard” 
virological endpoint 
Table 6:  Summary of the advantages and disadvantages of the four methodologies 
considered in this paper 
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FIGURES 
 
Figure 1: Vaccine effectiveness estimates over time split by statistical method and by consultation type 
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Supplemental Materials – 
Vaccination 
In 2010/11 no one particular seasonal influenza vaccine was delivered.  Table A documents 
the vaccine supplier, name of product and vaccine type for each manufacturer.  Vaccine lot 
numbers were incompletely recorded in the extract for vaccines used for each patient.  
 
All vaccines used were administered IM into deltoid muscle and in appropriate dose 
following manufacturer recommendations – vaccines administered were provided with 
needles already attached to barrel (see individual manufacturer for detail on gauge and 
needle length). All vaccine administration was in accordance with NHS Scotland 
recommendations for ensuring the maintenance of the cold chain.  None of the influenza 
vaccines for the 2010/11 season contained thiomersal as an added preservative. 
 
Concomitant vaccine administration into a different anatomical site (usually contralateral 
arm) for a small minority of individuals cannot be excluded for polysaccharide 
pneumococcal vaccination but this data was not collected (75% of those over the age of 65 
60-70% of those under the age of 65 in an at risk group have previously received 
polysaccharide vaccine. Each year as each age cohort turns 65 individuals without prior 
vaccination are offered pneumococcal polysaccharide vaccination.  Revaccination with 
pneumococcal polysaccharide vaccine is restricted to a small number of patients with 
chronic renal disease every five years.  The overall number of patients in any season 
receiving concomitant pneumococcal polysaccharide vaccination is estimated to be around 
1-2% of all influenza cases).   
 
Table A: Seasonal influenza vaccine characteristics in Scotland in 2010/11  
Supplier  Name of product  Vaccine Type  
GlaxoSmithKline  Fluarix  Split virion, inactivated  
MASTA  Imuvac  
Surface antigen, inactivated, sub-
unit  
Novartis Vaccines  
Agrippal  Surface antigen  
Begrivac  Split virion  
Fluvirin*  Surface antigen  
Pfizer Vaccines  
(formerly Wyeth 
Vaccines)  
Enzira  Split virion Inactivated  
Generic influenza vaccine  Split virion Inactivated  
Sanofi Pasteur MSD  
Inactivated influenza vaccine  Split virion  
Intanza**  Intradermal, split virion  
Solvay Healthcare  
Influvac  Surface antigen, inactivated, sub-
unit  
Imuvac  Surface antigen, inactivated, sub-
unit  
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Consultation Readcodes 
 
The ILI, ARI (including influenza and asthma) and ILIARI (including influenza and excluding 
asthma) consultation groupings were created using the following case definitions shown in 
Tables B-D. 
 
Table B: Asthma readcodes 
Readcode Readcode Description 
H33.. Asthma 
H330. Extrinsic (atopic) asthma 
H3300 Extrinsic asthma without status asthmaticus 
H3301 Extrinsic asthma with status asthmaticus 
H330z Extrinsic asthma NOS 
H331. Intrinsic asthma 
H3310 Intrinsic asthma without status asthmaticus 
H3311 Intrinsic asthma with status asthmaticus 
H331z Intrinsic asthma NOS 
H332. Mixed asthma 
H333. Acute exacerbation of asthma 
H334. Brittle asthma 
H33z. Asthma unspecified 
H33z0 Status asthmaticus NOS 
H33z1 Asthma attack 
H33z2 Late-onset asthma 
H33zz Asthma NOS 
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Table C: ARI readcodes 
Readcode Readcode Description 
H0... Acute respiratory infections 
H05.. Other acute upper respiratory infections 
H05z. Upper respiratory infection NOS 
H05z. Upper respiratory tract infection NOS 
H05z. Viral upper respiratory tract infection NOS 
H06.. Acute bronchitis and bronchiolitis 
H06z. Acute bronchitis or bronchiolitis NOS 
H07.. Chest cold 
H0y.. Other specified acute respiratory infections 
H22.. Other bacterial pneumonia 
H22.. Chest infection - other bacterial pneumonia 
H22y. Pneumonia due to other specified bacteria 
H23.. Pneumonia due to other specified organisms 
H23.. Chest infection - pneumonia organism OS 
H260. Lobar pneumonia due to unspecified organism 
H3... Chronic obstructive pulmonary disease 
H3... Chronic obstructive airways disease 
H33.. Asthma 
H33.. Bronchial asthma 
H333. Acute exacerbation of asthma 
Hyu1. [X]Other acute lower respiratory infections 
Hyu10 [X]Acute bronchitis due to other specified organisms 
H04.. Acute laryngitis and tracheitis 
H05y. Other upper respiratory infections of multiple sites 
H0z.. Acute respiratory infection NOS 
H22z. Bacterial pneumonia NOS 
H23z. Pneumonia due to specified organism NOS 
H25.. Bronchopneumonia due to unspecified organism 
H25.. Chest infection - unspecified bronchopneumonia 
H26.. Pneumonia due to unspecified organism 
H26.. 
Chest infection - pneumonia due to unspecified 
organism 
H33z0 Status asthmaticus NOS 
H33z0 Severe asthma attack 
Hyu0. [X]Acute upper respiratory infections 
Hyu11 [X]Acute bronchiolitis due to other specified organisms 
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Table D: ILI readcodes 
Readcode Readcode Description 
G5203 Acute myocarditis - influenza 
H2... Pneumonia and influenza 
H27.. Influenza 
H270. Influenza with pneumonia 
H270. Chest infection - influenza with pneumonia 
H2700 Influenza with bronchopneumonia 
H2701 Influenza with pneumonia, influenza virus identified 
H270z Influenza with pneumonia NOS 
H271. Influenza with other respiratory manifestation 
H2710 Influenza with laryngitis 
H2711 Influenza with pharyngitis 
H271z Influenza with respiratory manifestations NOS 
H27y. Influenza with other manifestations 
H27y0 Influenza with encephalopathy 
H27y1 Influenza with gastrointestinal tract involvement 
H27yz Influenza with other manifestations NOS 
H2y.. Other specified pneumonia or influenza 
H2z.. Pneumonia or influenza NOS 
Hyu05 [X]Influenza and other manifestations, influenza virus identified 
Hyu06 
[X]Influenza and other respiratory manifestations, virus not 
identified 
Hyu07 [X]Influenza and other manifestations, virus not identified 
 
 
 
